Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

RCT (n=805) did not demonstrate survival benefit with avelumab maintenance vs. continued chemotherapy (median overall survival, 10.4 vs. 10.9 months, respectively) in patients with advanced disease overall or in a prespecified PD-L1–positive population.

Journal of Clinical Oncology